Home / Business and Economy / US$7.25B Settlement: Bayer Aims to End Roundup Lawsuits
US$7.25B Settlement: Bayer Aims to End Roundup Lawsuits
11 Sep
Summary
- Bayer seeks court approval for a US$7.25 billion settlement.
- The deal aims to resolve tens of thousands of US cancer lawsuits.
- Payouts range from US$10,000 to US$165,000 for eligible claimants.
Bayer's Monsanto unit is presenting a US$7.25 billion settlement to a Missouri state court, aiming to resolve approximately 65,000 U.S. lawsuits alleging Roundup causes cancer. Judge Timothy Boyer will review the proposed deal, which seeks to address both current and future claims related to the weedkiller.
This litigation has significantly impacted Bayer since its 2018 acquisition of Monsanto. The settlement offers payouts ranging from US$10,000 to US$165,000 to individuals who developed non-Hodgkin lymphoma after using Roundup. Compensation amounts will vary based on factors such as cancer severity and exposure history.
While Bayer maintains that Roundup's active ingredient, glyphosate, is safe and not carcinogenic, the World Health Organization's International Agency for Research on Cancer classified glyphosate as a probable carcinogen in 2015. The U.S. Environmental Protection Agency, however, has stated it is not likely to cause cancer in humans under expected exposure levels. An updated EPA risk assessment for glyphosate is anticipated in late 2026.
